<code id='73934C1E5D'></code><style id='73934C1E5D'></style>
    • <acronym id='73934C1E5D'></acronym>
      <center id='73934C1E5D'><center id='73934C1E5D'><tfoot id='73934C1E5D'></tfoot></center><abbr id='73934C1E5D'><dir id='73934C1E5D'><tfoot id='73934C1E5D'></tfoot><noframes id='73934C1E5D'>

    • <optgroup id='73934C1E5D'><strike id='73934C1E5D'><sup id='73934C1E5D'></sup></strike><code id='73934C1E5D'></code></optgroup>
        1. <b id='73934C1E5D'><label id='73934C1E5D'><select id='73934C1E5D'><dt id='73934C1E5D'><span id='73934C1E5D'></span></dt></select></label></b><u id='73934C1E5D'></u>
          <i id='73934C1E5D'><strike id='73934C1E5D'><tt id='73934C1E5D'><pre id='73934C1E5D'></pre></tt></strike></i>

          focus

          focus

          author:hotspot    Page View:8828
          Checkpoint inhibitor
          Adobe

          ITeos Therapeutics offered the first look at clinical data for its experimental cancer antibody that works by blocking the novel — and very buzzworthy — protein target called TIGIT.

          The tumor-shrinking activity of the company’s drug, called EOS-448, was minimal but still comparable to early study data from competing TIGIT-targeted drugs in development, including ones from Roche and Merck.

          advertisement

          iTeos presented the EOS-448 Phase 1 study results at the annual meeting of the American Association for Cancer Research on Saturday.

          STAT+ Exclusive Story

          Already have an account? Log in

          STAT+

          This article is exclusive to STAT+ subscribers

          Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

          Already have an account? Log in

          Already have an account? Log in

          Monthly

          $39

          Totals $468 per year

          $39/month Get Started

          Totals $468 per year

          Starter

          $30

          for 3 months, then $39/month

          $30 for 3 months Get Started

          Then $39/month

          Annual

          $399

          Save 15%

          $399/year Get Started

          Save 15%

          11+ Users

          Custom

          Savings start at 25%!

          Request A Quote Request A Quote

          Savings start at 25%!

          2-10 Users

          $300

          Annually per user

          $300/year Get Started

          $300 Annually per user

          View All Plans

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In

          explore

          Duchenne breakthrough therapy leaves behind pioneering families
          Duchenne breakthrough therapy leaves behind pioneering families

          DuchennemusculardystrophyDr.EdwinP.Ewing,Jr./CDCPatFurlongwassittinginherhomeofficeinMiddletown,Ohio

          read more
          Readout Newsletter: New research from Sanofi, Regeneron, etc.
          Readout Newsletter: New research from Sanofi, Regeneron, etc.

          HyacinthEmpinado/STATWanttostayontopofthescienceandpoliticsdrivingbiotechtoday? Signup togetourbiote

          read more
          DIEP, the 'gold standard' of breast reconstruction, is under threat
          DIEP, the 'gold standard' of breast reconstruction, is under threat

          AdobeIn1983,Iflewhomefromcollegetobewithmymotherasshewokeupfromamastectomy.Sheoptedoutofbreastrecons

          read more

          FDA panel unanimously endorses Eisai’s Alzheimer’s drug Leqembi

          AdobeExpertadviserstotheFoodandDrugAdministrationonFridayvotedunanimouslyinfavorof expandingtheappro